Lambrolizumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | PD-1 |
| Clinical data | |
| Legal status | Investigational |
| Routes | IV |
| Identifiers | |
| CAS number | 1374853-91-4 |
| ATC code | None |
| Chemical data | |
| Formula | C6504H10004N1716O2036S46 (peptide) |
| Mol. mass | 146.3 kDa (peptide) |
Lambrolizumab (also known as MK-3475) is a drug in development by Merck that targets the programmed cell death 1 (PD-1) receptor. The drug is intended for use in treating metastatic melanoma.[1]
References
- ↑ PMID 23724846 (PubMed)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.